DTBN
Pulsar + sobre un periodo para mostrar cada año
What role can dabigatran, rivaroxaban and apixaban play in the future?
Biotechnology drugs and cancer. All that glitters is not gold
Ibandronate and the prevention of non-vertebral fractures. A critical appraisal of two meta-analyses on individual patient data
DTB Navarre. Vol 18, No 2. March - April 2010
Patient safety, beware of medication errors!
Suicide and antidepressants
Rosuvastatin and the JUPITER trial. A critical appraisal
Atrial fibrillation, rhythm or rate control?
Quality related problems in clinical practice guidelines
Denosumab in osteoporosis-related fractures. A critical appraisal of the FREEDOM trial
Calcium supplements: Are we doing it right?
Medicalization of aging and the testosterone deficiency syndrome
Antipsychotic therapy after failure with first-line treatment: should we increase the dose, switch drugs, or combine antipsychotics?
Drugs and QT interval prolongation
Multicasuality of falls and the role of drugs
The challenge of managing multimorbility
Roflumilast for stable COPD, another example of hasty positioning in (some) Clinical Practice Guidelines
Pay attention to the Attention Deficit Hyperactive Disorder (ADHD). Between an uncertain nature and a hyperactive prescription
Melatonin for sleep disorders
Strategies for discontinuing benzodiazepines